Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • Article
  • Health Affairs

Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users

By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
  • Format:Print
ShareBar

Abstract

Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling pharmaceutical spending. This study explores the early years of entry of biosimilars and related follow-on products in the US. Using monthly sales data from the period 2005–19 for ten drug classes, we examine how quickly biosimilars/follow-on products gained market share and the subsequent trajectory of prevailing (national average invoice) prices. Our analysis suggests that although uptake has been slower than what is typically seen in generic drug markets, the most recent entrants have captured market share more rapidly than comparable earlier biosimilars/follow-on products. We also document that from biosimilar/follow-on products’ time of entry, their lower prices help offset the overall trend in average annual reference-product price increases. Our findings can provide insight into future policy reforms aimed at increasing competition and use of biosimilars, leading to expanded patient access and significant cost savings.

Keywords

Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States

Citation

Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021).
  • Find it at Harvard
  • Purchase

About The Author

Ariel D. Stern

Technology and Operations Management
→More Publications

More from the Authors

    • April 18, 2022
    • Harvard Business Review (website)

    Will mRNA Technology Companies Spawn Innovation Ecosystems?

    By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
    • April 2022
    • NEJM Catalyst Innovations in Care Delivery

    AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care

    By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
    • March 2022
    • Faculty Research

    Proximie: Using XR Technology to Create Borderless Operating Rooms

    By: Ariel D. Stern and Alpana Thapar
More from the Authors
  • Will mRNA Technology Companies Spawn Innovation Ecosystems? By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
  • AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
  • Proximie: Using XR Technology to Create Borderless Operating Rooms By: Ariel D. Stern and Alpana Thapar
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College